Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)

Condition(s) studied

Investigational drug(s) / intervention(s)

Clopidogrel: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel

Ticagrelor: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel

Study summary

Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients to Clopidogrel undergoing carotid stenting and Clopidogrel in "responders" undergoing carotid stenting, in the onset of death and major adverse cardiovascular events (MACE) and bleeding events, 1 and 3 months after the procedure. Furthermore, the study aims to evaluate the possible preoperative clinical and pharmacological factors most associated with the phenomenon of resistance to Clopidogrel.

Inclusion criteria:

The data will be collected on adult patients (age\> 18 years) who have given their consent to participate in the study, belonging to the U.O. of Vascular Surgery of the IRCCS Policlinico San Donato and the U.O. of Vascular Surgery of the participating centers and there subjected to the treatment of carotid stenosis by stenting technique.

Exclusion criteria:

Those patients who are minors, who have not given their consent to participate in the study, or who have carotid stenosis not susceptible to intervention by stenting will be excluded from the study. Pregnant or lactating women will also be excluded from the study (such as situations in which carotid stenting is contraindicated regardless of the execution of the study).

Eligibility

Primary outcome measure(s)

• Death — 1 month
  Outpatient visit
• Death — 3 months
  Outpatient visit
• MACE — 1 month
  Major Adverse Cardiovascular Events, Outpatient visit
• MACE — 3 months
  Major Adverse Cardiovascular Events, Outpatient visit
• Occurrence of major hemorrhagic events — 1 month
  Outpatient visit
• Occurrence of major hemorrhagic events — 3 months
  Outpatient visit

Trial sites (1)

On this site

More IRCCS Policlinico S. Donato trials in Italy

Other trials for the same condition